AR051293A1 - Inhibidores bace - Google Patents
Inhibidores baceInfo
- Publication number
- AR051293A1 AR051293A1 ARP050103898A ARP050103898A AR051293A1 AR 051293 A1 AR051293 A1 AR 051293A1 AR P050103898 A ARP050103898 A AR P050103898A AR P050103898 A ARP050103898 A AR P050103898A AR 051293 A1 AR051293 A1 AR 051293A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- cycloalkyl
- alkyl
- fluoro
- phenyl
- Prior art date
Links
- 102100021257 Beta-secretase 1 Human genes 0.000 title abstract 2
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 13
- 125000001153 fluoro group Chemical group F* 0.000 abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000002541 furyl group Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyano, methyl Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 150000003573 thiols Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Abstract
La presente proporciona inhibidores BACE de formula (1) procedimientos para su uso y preparacion, e intermedios utiles para su preparacion. Reivindicacion 1: Un compuesto de formula (1) en la que: R1 es alquilo C1-8 opcionalmente sustituido con cicloalquilo C3-8, fenilo, o furilo; alquenilo C2-8 opcionalmente sustituido con cicloalquilo C3-8, fenilo, o furilo; alquinilo C2-8 opcionalmente sustituido con cicloalquilo C3-8, fenilo, o furilo; o cicloalquilo C3-8; cada uno opcionalmente sustituido hasta seis veces con fluoro, o con hasta cuatro sustituyentes seleccionados independientemente entre el grupo constituido por halo, ciano, metilo opcionalmente sustituido con hasta tres átomos de F, trifluorometoxi, alcoxi C1-6, cicloalcoxi C3-7, oxo, NR7R8, y C(O)NR7R7; o R1 es H; furilo; tienilo; tetrahidrofurilo; NR7R8, o alcoxi C1-6; R2 es alquilo C1-3 opcionalmente sustituido con cicloalquilo C3-6; bencilo opcionalmente monosustituido en el anillo fenilo con un sustituyente seleccionado entre el grupo constituido por halo, hidroxi, tiol, benciloxi, alquilo C1-6 opcionalmente sustituido en la cadena alquilo con cicloalquilo C3-8 o hasta tres veces con fluoro, alcoxi C1-6 opcionalmente sustituido en la cadena alquilo con cicloalquilo C3-8 o hasta tres veces con fluoro, alqueniloxi C2-6, y alquil C1-6tio opcionalmente sustituido en la cadena alquilo con cicloalquilo C3-8 o hasta tres veces con fluoro, bencilo disustituido en el anillo fenilo con un primer sustituyente seleccionado entre el grupo constituido por halo, trifluorometoxi, y alquilo C1-6 opcionalmente sustituido en la cadena alquilo con cicloalquilo C3-8 o hasta tres veces con fluoro, y un segundo sustituyente seleccionado entre el grupo constituido por halo, alquilo C1-6 opcionalmente sustituido en la cadena alquilo con cicloalquilo C3-8 o hasta tres veces con fluoro, alcoxi C1-6 opcionalmente sustituido en la cadena alquilo con cicloalquilo C3-8 o hasta tres veces con fluoro, alqueniloxi C2-6, y alquil C1-6tio opcionalmente sustituido en la cadena alquilo con ciclolquilo C3-8 o hasta tres veces con fluoro, o bencilo trisustituido en el anillo fenilo con sustituyentes seleccionados independientemente entre halo; R3 es H o alquilo C1-6 opcionalmente sustituido con cicloalquilo C3-8 o hasta tres veces con fluoro; R4 es H o alquilo C1-6; R3 y R4 tomados juntos con el átomo de C al que están unidos forman un anillo cicloalquilo C3-6; R5 es H; R9; o -(CH2)0-2- OR9; R6 es H o fenilo; G es O o S(O)0-2; R7 se selecciona independientemente encada caso entre el grupo constituido por H, alquilo C1-6, y fenilo; R8 es H; alquilo C1-6; fenilo, -C(O)(alquilo C1-6), o -SO2(alquilo C1-6); R9 es H, alquilo C1-10 opcionalmente sustituido con 1-6 átomos de F; acilo C2-10, alquenilo C2-6, o -(CH2)0-4-R10; R10 es cicloalquilo C3-8; cicloalcanona C3-8; tetrahidrofurilo; tetrahidropiranilo; o fenilo cada uno opcionalmente sustituido con un sustituyente seleccionado entre el grupo constituido por cicloalquilo C3-8, fenilo, y bencilo, hasta cuatro veces con fluoro, o con uno o dos sustituyentes seleccionados independientemente entre el grupo constituido por halo, alquilo C1-6 opcionalmente sustituido hasta tres veces con fluoro, acilo C2-6, alcoxi C1-6, hidroxi, y trifluorometoxi; o R10 es adamantilo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61171804P | 2004-09-21 | 2004-09-21 | |
| US69694905P | 2005-07-06 | 2005-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051293A1 true AR051293A1 (es) | 2007-01-03 |
Family
ID=35976430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103898A AR051293A1 (es) | 2004-09-21 | 2005-09-20 | Inhibidores bace |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7745438B2 (es) |
| EP (1) | EP2091928A2 (es) |
| JP (1) | JP2008513539A (es) |
| AR (1) | AR051293A1 (es) |
| CA (1) | CA2577799A1 (es) |
| PE (1) | PE20060692A1 (es) |
| SV (1) | SV2006002232A (es) |
| TW (1) | TW200624426A (es) |
| WO (1) | WO2006034093A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| JP2007533740A (ja) | 2004-04-22 | 2007-11-22 | イーライ リリー アンド カンパニー | Ｂａｃｅ阻害剤としてのアミド |
| US7585885B2 (en) | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
| KR101404360B1 (ko) | 2006-09-05 | 2014-06-09 | 교와 핫꼬 기린 가부시키가이샤 | 이미다졸 유도체 |
| UY32799A (es) | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| US8188079B2 (en) * | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| WO2011154431A1 (en) | 2010-06-09 | 2011-12-15 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| TWI421250B (zh) | 2010-07-13 | 2014-01-01 | Novartis Ag | 衍生物及其用於治療神經性疾病之用途 |
| AU2011347377B2 (en) | 2010-12-22 | 2016-03-03 | Janssen Pharmaceutica Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| US8524897B2 (en) * | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
| EA024059B1 (ru) | 2011-01-13 | 2016-08-31 | Новартис Аг | Гетероциклические производные и их применение в лечении неврологических расстройств |
| US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
| SI2681219T1 (sl) | 2011-03-01 | 2016-02-29 | Janssen Pharmaceutica, N.V. | Derivati 6,7-dihidro-pirazolo(1,5-a)pirazin-4-ilamina uporabni kot inhibitorji beta-sekretaze (BACE) |
| ES2534973T3 (es) | 2011-03-09 | 2015-04-30 | Janssen Pharmaceutica N.V. | Derivados de 3,4-dihidro-pirrolo[1,2-a]pirazin-1-ilamina útiles como inhibidores de beta-secretasa (BACE) |
| US9079919B2 (en) * | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| EP2718287A1 (en) * | 2011-06-07 | 2014-04-16 | F.Hoffmann-La Roche Ag | [1,3]oxazines |
| CA2837252A1 (en) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| US10202355B2 (en) | 2013-02-12 | 2019-02-12 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| EP3008066B1 (en) | 2013-06-12 | 2018-08-15 | Janssen Pharmaceutica N.V. | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace) |
| CN105452251B (zh) | 2013-06-12 | 2017-12-26 | 詹森药业有限公司 | 作为β‑分泌酶(BACE)抑制剂的4‑氨基‑6‑苯基‑5,6‑二氢咪唑并[1,5‑A]吡嗪‑3(2H)‑酮衍生物 |
| CN105324383B (zh) | 2013-06-12 | 2017-10-31 | 詹森药业有限公司 | 作为β‑分泌酶(BACE)抑制剂的4‑氨基‑6‑苯基‑6,7‑二氢[1,2,3]三唑并[1,5‑A]吡嗪衍生物 |
| EP3078659B1 (en) * | 2013-12-02 | 2017-11-15 | Jenkem Technology Co., Ltd. (Beijing) | 3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof |
| EP3233834B1 (en) | 2014-12-18 | 2019-11-13 | Janssen Pharmaceutica NV | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine derivatives useful as inhibitors of beta-secretase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0395664A1 (en) | 1987-10-21 | 1990-11-07 | The Upjohn Company | Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety |
| JP2004538274A (ja) * | 2001-07-10 | 2004-12-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療するためのα−ヒドロキシアミドスタチン誘導体 |
| US6673821B2 (en) * | 2001-10-22 | 2004-01-06 | Enanta Pharmaceuticals, Inc. | Nitrogen heterocycle inhibitors of aspartyl protease |
| UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
| ATE443043T1 (de) * | 2002-11-12 | 2009-10-15 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| JP4198086B2 (ja) | 2003-06-25 | 2008-12-17 | オリンパス株式会社 | 蛍光観察用装置 |
| JP4448134B2 (ja) * | 2003-08-08 | 2010-04-07 | シェーリング コーポレイション | ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤 |
| JP2007533740A (ja) | 2004-04-22 | 2007-11-22 | イーライ リリー アンド カンパニー | Ｂａｃｅ阻害剤としてのアミド |
| US7388007B2 (en) * | 2004-08-26 | 2008-06-17 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
-
2005
- 2005-09-19 PE PE2005001080A patent/PE20060692A1/es not_active Application Discontinuation
- 2005-09-19 TW TW094132231A patent/TW200624426A/zh unknown
- 2005-09-19 SV SV2005002232A patent/SV2006002232A/es not_active Application Discontinuation
- 2005-09-20 JP JP2007533560A patent/JP2008513539A/ja active Pending
- 2005-09-20 CA CA002577799A patent/CA2577799A1/en not_active Abandoned
- 2005-09-20 EP EP05798832A patent/EP2091928A2/en not_active Withdrawn
- 2005-09-20 WO PCT/US2005/033277 patent/WO2006034093A2/en active Application Filing
- 2005-09-20 US US11/574,989 patent/US7745438B2/en not_active Expired - Fee Related
- 2005-09-20 AR ARP050103898A patent/AR051293A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070225267A1 (en) | 2007-09-27 |
| CA2577799A1 (en) | 2006-03-30 |
| PE20060692A1 (es) | 2006-07-19 |
| WO2006034093A3 (en) | 2006-07-13 |
| WO2006034093A2 (en) | 2006-03-30 |
| SV2006002232A (es) | 2006-05-25 |
| TW200624426A (en) | 2006-07-16 |
| US7745438B2 (en) | 2010-06-29 |
| EP2091928A2 (en) | 2009-08-26 |
| JP2008513539A (ja) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051293A1 (es) | Inhibidores bace | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| AR056764A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| AR054417A1 (es) | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. | |
| AR048260A1 (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| AR056047A1 (es) | Derivados de bencil - benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, su uso y procedimiento para su preparacion. | |
| AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| AR049448A1 (es) | Biciclooctenos sustituidos y usos como herbicidas | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| AR064010A1 (es) | Inhibidores de la actividad de la akt | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| CO6180424A2 (es) | Inhibodores espiro cetona de acetil-coa carboxilasa | |
| AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
| AR085318A1 (es) | Derivados de triazol que tienen actividad insecticida | |
| AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| DE602006018135D1 (de) | Imidazo- und triazolopyridine als inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR029887A1 (es) | Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
| AR076579A1 (es) | Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |